AstraZeneca is trying to blaze a new trial for immunotherapy in liver cancer with its EMERALD-1 trial, but the jury is out on its prospects. The study of PD-L1 inhibitor Imfinzi (durvalumab ...
AIM ImmunoTech (AIM) announced Safety Committee approval to proceed with the Phase 2 portion of the Phase 1b/2 clinical trial involving AIM’s ...
it recently chalked up an impressive win for Imfinzi in hepatocellular carcinoma (HCC) – the most common form of liver cancer – in the EMERALD-1 study. “Our goal with the PACIFIC-2 trial was ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback